Cognito TX

Cognito TX, founded in 2016 and based in Cambridge, Massachusetts, building on groundbreaking research from MIT neuroscientists Li-Huei Tsai and Ed Boyden, focuses on developing innovative, disease-modifying neuromodulation treatments for neurodegenerative diseases. The company is pioneering a non-invasive neuromodulation treatment for AD using a wearable device that delivers proprietary gamma-frequency light and sound stimulation. This technology aims to stimulate gamma wave activity in the brain, which is believed to play a critical role in memory and cognitive function, potentially slowing cognitive decline and preserving brain structure in patients with Alzheimer’s. The device has shown promising results in clinical studies, including a Phase 2 trial that demonstrated reduced brain atrophy and slowed cognitive decline, and it has received FDA Breakthrough Device Designation for its potential in treating Alzheimer’s.

CEO and Co-founders: Christian Howell, Li-Huei Tsai and Ed Boyden